NNC 0070 0002 0349Alternative Names: NNC 0070-0002-0349
Latest Information Update: 24 Sep 2014
At a glance
- Originator Novo Nordisk
- Class Obesity therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 24 Sep 2014 Discontinued - Phase-I for Obesity (In volunteers) in USA (SC)